Scotiabank upgraded Danaher (DHR) to Outperform from Sector Perform with a price target of $275, up from $265. The firm believes the “worst-case outlook” for life science tools companies has been largely factored into valuations. The sector’s longer-term fundamentals are mostly unchanged and growth acceleration should occur into 2026 and beyond, the analyst tells investors in a research note. As a result, Scotiabank expects further upside in the stocks, driving upgrades of both Danaher and Thermo Fisher.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher upgraded to Outperform from Sector Perform at Scotiabank
- Danaher names Martin Stumpe as Chief Technology and AI Officer
- Danaher price target raised to $225 from $215 at Barclays
- Danaher’s SCIEX announces three software ecosystem enhancements
- SCIEX, Evosep expand access to standardized proteomics